Which is better, KPV or LL-37?
LL-37 has the higher evidence grade (human RCT) because a 34 patient phase I/II trial found faster venous ulcer healing with the two lower gel doses, but a larger phase IIb trial did not confirm it overall, and no data exist for injected LL-37. KPV is animal only and, like LL-37, is not on the 503A bulks list; topical or oral KPV is covered by HHS's draft enforcement discretion policy (FDA's drug center recommended against listing; the advisory committee voted in favor, per HHS's Appendix B), while LL-37 is not covered and has no lawful compounded path. For a chronic wound, LL-37 gel is the one with human data; for gut inflammation or systemic use, neither has human evidence. [1] [2] [3] [4] [5] [10]
How do KPV and LL-37 compare?
| Dimension | KPV | LL-37 |
|---|---|---|
| What it is [3] [6] | Synthetic tripeptide (lysine-proline-valine), the C-terminal fragment of alpha-MSH. | Human cathelicidin antimicrobial peptide (37 amino acids) cleaved from the hCAP18 precursor. |
| Mechanism [3] [6] | Taken into gut and immune cells by PepT1, then inhibits NF-kB and MAP kinase inflammatory signaling. | Disrupts bacterial membranes, neutralizes lipopolysaccharide, recruits immune cells through FPR2, and stimulates keratinocyte migration and angiogenesis. |
| Direction of immune effect [6] [7] | Anti-inflammatory: dampens cytokine release. | Mixed: antimicrobial and pro healing at low concentrations, but pro inflammatory and cytotoxic at high concentrations and elevated in psoriasis and rosacea lesions. |
| Human evidence [1] [2] [3] | No indexed human trial for any indication. | Two randomized trials of topical gel in venous leg ulcers: faster healing at the two lower concentrations in 34 patients; the phase IIb trial missed its primary endpoint overall. |
| Main animal evidence [3] [6] [7] | Reduced DSS and TNBS colitis in mice, confirmed by a second lab in DSS and T cell transfer colitis. | Accelerated wound healing and protected against bacterial infection in rodent skin, lung, and sepsis models. |
| Theoretical safety concern [3] [6] | Immune dampening could impair response to infection (not shown). | May worsen psoriasis, rosacea, or lupus, where it is thought to drive inflammation; cytotoxic at high concentrations. |
| FDA and compounding status [4] [5] [10] [11] | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (topical or oral only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). | Nomination withdrawn: in no 503A category, not on the bulks list, not reviewed at the July 2026 PCAC meeting, and not covered by HHS's October 2026 draft policy, so it has no lawful compounded path. |
| WADA status [8] | Prohibited at all times under S0 (non-approved substances). | Prohibited at all times under S0 (non-approved substances). |
| Typical cost and access [4] [5] [9] [10] | No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price. Injectable KPV is not covered. | No lawful compounded price: nomination withdrawn, not on the 503A bulks list, not reviewed by PCAC, and not covered by HHS's draft policy. Research chemical vials sold for human use are unapproved drugs. |
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | KPV | LL-37 |
|---|---|---|
| Class | Synthetic tripeptide (lysine-proline-valine), the C-terminal fragment of alpha-melanocyte stimulating hormone (alpha-MSH) | Human cathelicidin antimicrobial peptide (37 amino acids, cleaved from the hCAP18 precursor) |
| What it is | Anti-inflammatory fragment of the hormone alpha-MSH; mouse colitis data, no human trial; topical and oral use in HHS's October 2026 draft policy. | The only human cathelicidin, a germ-killing peptide. A skin gel had two small leg ulcer RCTs; no human data for injections. Off FDA Category 2 since April 2026. |
| Evidence | Evidence: Animal-only evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: HHS interim policy (draft) | Regulatory: Nomination withdrawn |
| Compounding | KPV is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds KPV when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (topical or oral only), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. Oral forms also need documentation that the formulation is adequately absorbed by mouth in humans. The draft policy is not an FDA approval, does not add KPV to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs. | Not an FDA approved drug. FDA lists cathelicidin LL-37 among the bulk substances whose Category 2 nominations were withdrawn, so as of the last verification date it sits in no 503A category and is outside FDA's interim policy for Category 1 substances. FDA has said it will ask the Pharmacy Compounding Advisory Committee to consider LL-37 for the 503A bulks list at a meeting before the end of February 2027, but no date is set and no rule has been proposed. Because it is not on the bulks list and is not part of an approved drug, a 503A pharmacy has no federal basis to compound it from bulk. Not eligible for 503B outsourcing. |
| WADA | WADA: WADA prohibited | WADA: WADA prohibited |
| Routes | Oral capsule (as sold), Subcutaneous injection (as sold), Topical cream and nasal spray (as sold), Oral in drinking water and intraperitoneal (mouse studies) | Topical gel on chronic wounds (clinical trials), Subcutaneous injection (as sold, no human data), Nebulized or intranasal (as sold, no human data) |
| Typical cost | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient KPV on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. | Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. Not routinely available through licensed telehealth or compounding channels as of the last verified date. |
| Last verified |
Has KPV been tested directly against LL-37?
No published trial has compared KPV and LL-37 directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do KPV and LL-37 cost?
| Dimension | KPV | LL-37 |
|---|---|---|
| Typical cost | No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient KPV on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. | Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. Not routinely available through licensed telehealth or compounding channels as of the last verified date. |
| Price detail | KPV price by channel | Price index in progress |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the KPV page and the LL-37 page.
Frequently asked questions
Which has better evidence, KPV or LL-37?
LL-37, but only for a topical gel on venous leg ulcers: a 34 patient trial showed faster healing at the two lower doses, while a larger phase IIb trial missed its primary endpoint. KPV has only mouse data. Neither has human data for injection. [1] [2] [3]
Which is better for gut inflammation?
Neither has been tested in people with gut inflammation. KPV has two independent mouse colitis studies; LL-37 was studied for skin wounds and infection, not bowel disease. [3] [6] [7]
Can LL-37 make inflammatory skin disease worse?
Possibly. LL-37 is elevated in psoriasis and rosacea lesions, where it can complex with self DNA and RNA to activate immune cells, so it is thought to drive inflammation in those conditions. KPV works in the opposite direction by dampening inflammatory signaling. [3] [6]
Can a pharmacy compound KPV or LL-37?
KPV possibly, under conditions; LL-37, no. Neither is on the 503A bulks list. KPV is covered by HHS's October 28, 2026 draft enforcement discretion policy, which says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (topical or oral only) on a patient-specific prescription, when sourcing, testing, and adverse event reporting conditions are met. Injectable KPV is not covered. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. LL-37 is not covered: its nomination was withdrawn and it was not reviewed by the committee, so it sits in no 503A category and has no lawful compounded path. State law still applies. [4] [5] [10] [11]
Are KPV and LL-37 allowed in sport?
No. Both are prohibited at all times under S0 of the WADA Prohibited List as non-approved substances. [8]
Conditions studied
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Gronberg A et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen 2014PubMed 25041740, 2014
- [2]Mahlapuu M et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: a multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen 2021PubMed 34687253, 2021
- [3]Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008PubMed 18061177, 2008
- [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [5]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [6]Vandamme D et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012PubMed 23246832, 2012
- [7]Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008PubMed 18092346, 2008
- [8]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [9]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [10]HHS: Draft enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendix A (the six covered peptides) and Appendix B (identity, route limits, and review history), October 28, 20262026
- [11]Federal Register notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496 (public inspection copy filed October 28, 2026; publication scheduled October 30, 2026)Federal Register, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). KPV vs LL-37: evidence, cost, and legality. https://peptideagent.ai/compare/kpv-vs-ll-37- HTML link
<a href="https://peptideagent.ai/compare/kpv-vs-ll-37">KPV vs LL-37: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.